Combination chemotherapy with capecitabine (C), irinotecan (I), oxaliplatin (O), and bevacizumab (B; XELOXIRIA) as first-line treatment of metastatic colorectal cancer (MCRC): Preliminary results of a phase I-II trial.

被引：0
|
作者：
Bazarbashi, S. [1 ]
Aljubran, A. H. [1 ]
Soudy, H. [1 ]
Darwish, A. [1 ]
Eltigani, A. [1 ]
Nabil-Ahmed, M. [1 ]
Edesa, W. [1 ]
Almubarak, M. [1 ]
Abu Sabaa, A. [1 ]
Shoukri, M. [1 ]
机构：
[1] King Faisal Specialist Hosp & Res Ctr, Riyadh 11211, Saudi Arabia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.e14073
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14073
引用
收藏
页数：1
相关论文
共 50 条
  • [31] First-line treatment with infusional 5-FU, leucovorin, and irinotecan plus bevacizumab (FOLFIRI-B) for metastatic colorectal cancer (MCRC): Preliminary results of a phase II trial
    Kopetz, S.
    Glover, K.
    Eng, C.
    Adinin, R.
    Morris, J.
    Wolff, R.
    Lin, E.
    Chang, D.
    Abbruzzese, J.
    Hoff, P.
    ANNALS OF ONCOLOGY, 2006, 17 : 73 - 73
  • [32] IXOA regimen, irinotecan (I), capecitabine (X), oxaliplatin (O), and bevacizumab (A), as first-line therapy for advanced unresectable colorectal cancer (aCRC): Preliminary results.
    Maroun, Jean Alfred
    Jonker, Derek J.
    Cripps, M. Christine
    Goel, Rakesh
    Asmis, Timothy R.
    Goodwin, Rachel Anne
    Yarom, Nirit
    Marginean, Horia
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [33] BEVACIZUMAB (BV) IN COMBINATION WITH FOLFOXIRI (IRINOTECAN, OXALIPLATIN AND INFUSIONAL 5FU/LV) AS FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER (mCRC): A PHASE II TRIAL BY THE GONO GROUP
    Masi, G.
    Vasile, E.
    Loupakis, F.
    Salvatore, L.
    Fornaro, L.
    Baldi, G.
    Stasi, I
    Cupini, S.
    Ciarlo, A.
    Del Monte, F.
    Trenta, P.
    Mezi, S.
    Rondini, M.
    Andreuccetti, M.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2009, 20 : 12 - 12
  • [34] Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group
    Schmiegel, W.
    Reinacher-Schick, A.
    Arnold, D.
    Kubicka, S.
    Freier, W.
    Dietrich, G.
    Geissler, M.
    Hegewisch-Becker, S.
    Tannapfel, A.
    Pohl, M.
    Hinke, A.
    Schmoll, H. J.
    Graeven, U.
    ANNALS OF ONCOLOGY, 2013, 24 (06) : 1580 - 1587
  • [35] Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a Phase I study
    H Y Sheikh
    J W Valle
    K Palmer
    A Sjursen
    O Craven
    G Wilson
    R Swindell
    M P Saunders
    British Journal of Cancer, 2007, 96 : 38 - 43
  • [36] Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a Phase I study
    Sheikh, H. Y.
    Valle, J. W.
    Palmer, K.
    Sjursen, A.
    Craven, O.
    Wilson, G.
    Swindell, R.
    Saunders, M. P.
    BRITISH JOURNAL OF CANCER, 2007, 96 (01) : 38 - 43
  • [37] MULTICENTER PHASE II STUDY OF BEVACIZUMAB, OXALIPLATIN AND CAPECITABINE AS FIRST-LINE CHEMOTHERAPY IN METASTATIC COLORECTAL CANCERS: KOREA CANCER STUDY GROUP TRIAL: PRELIMINARY DATA
    Lee, S. S.
    Kim, T. W.
    Ahn, J. B.
    Jung, K. H.
    Im, S.
    Kim, J. H.
    Park, Y. S.
    ANNALS OF ONCOLOGY, 2008, 19 : 146 - 146
  • [38] A phase II trial of gefitinib in combination with capecitabine and oxaliplatin as first-line chemotherapy in patients with advanced colorectal cancer
    Gelibter, Alain J.
    Gamucci, Teresa
    Pollera, Camillo F.
    Di Costanzo, Francesco
    Nuzzo, Carmen
    Gabriele, Angela
    Signorelli, Carlo
    Gasperoni, Silvia
    Ferraresi, Virginia
    Giannarelli, Diana
    Cognetti, Francesco
    Zeuli, Massimo
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (09) : 2117 - 2123
  • [39] Pharmacokinetic (PK) interactions between capecitabine (X), oxaliplatin (O) and bevacizumab (A) when used in combination for first-line treatment of metastatic colorectal cancer (MCRC)
    Brennan, B.
    Siu, L.
    Dhesy-Thind, B.
    Cripps, C.
    Gandhi, A.
    Abt, M.
    Smith, K.
    Rittweger, K.
    Hussain, S.
    Choudhury, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [40] Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first-line treatment for metastatic colorectal cancer: Safety lead-in results from the QUATTRO-II study
    Kotani, Daisuke
    Yoshino, Takayuki
    Kotaka, Masahito
    Kawazoe, Akihito
    Masuishi, Toshiki
    Taniguchi, Hiroya
    Yamazaki, Kentaro
    Yamanaka, Takeharu
    Oki, Eiji
    Muro, Kei
    Komatsu, Yoshito
    Bando, Hideaki
    Satake, Hironaga
    Kato, Takeshi
    Tsuji, Akihito
    INVESTIGATIONAL NEW DRUGS, 2021, 39 (06) : 1649 - 1655
12345